Marksans Pharma (NSE:MARKSANS) filed a press release on 12 August 2026 reporting unaudited consolidated financial results for Q1FY27 (quarter ended 30 June 2026). The company recorded consolidated EBITDA of Rs 213 crore, up 112.8% year-on-year, and PAT of Rs 159 crore, up 173.9% YoY.
Key Highlights
- Consolidated operating revenue rose 35.6% YoY to Rs 840.8 crore in Q1FY27, with EBITDA margin expanding 919 basis points YoY to 25.3%.
- UK and Europe formulation revenue reached an all-time quarterly high of Rs 356 crore, up 74.7% YoY, including a Rs 44 crore contribution from newly acquired QliniQ B.V.
- Cash balance crossed Rs 1,000 crore for the first time, closing the quarter at Rs 1,058 crore, with net cash of Rs 1,031 crore.
- India Ratings and Research (Fitch Group) revised the outlook on the company's bank loan facilities to Positive from Stable, with ratings affirmed at IND AA-/IND A1+.
About the Company
Marksans Pharma Limited (NSE:MARKSANS; BSE: 524404) is a Mumbai-headquartered generic pharmaceutical formulation company engaged in research, manufacturing, and marketing across global markets. Its manufacturing facilities carry approvals from USFDA, UKMHRA, and Australian TGA. The company's product portfolio spans CVS, CNS, antidiabetic, pain management, gastroenterological, and anti-allergy therapeutic segments.
Announcement in Detail
For Q1FY27, Marksans Pharma reported consolidated operating revenue of Rs 840.8 crore (up 35.6% YoY), gross profit of Rs 497.3 crore at a margin of 59.1%, EBITDA of Rs 213 crore at a margin of 25.3%, and PAT of Rs 159.4 crore at a net margin of 18.4%. EPS for the quarter stood at Rs 3.5, compared to Rs 1.3 in Q1FY26.
By geography, US and North America contributed Rs 377.2 crore (up 15.1% YoY), UK and Europe Rs 356 crore (up 74.7% YoY), Australia and New Zealand Rs 87.6 crore (up 53.7% YoY), and Rest of World Rs 20 crore (down 36.8% YoY). The company completed the acquisition of 100% of QliniQ B.V. and ABCnow in Europe during the quarter. Free cash flow stood at Rs 152 crore and R&D spend was Rs 23 crore, representing 2.8% of consolidated revenue.
Impact on Investors
The filing shows a substantial improvement in profitability metrics across both margin and absolute terms. Shareholders will observe that EBITDA margin widened by 919 basis points YoY to 25.3%, and PAT margin expanded by 910 basis points YoY to 18.4%. The working capital cycle improved to approximately 132 days in Q1FY27 from approximately 159 days in Q1FY26, as disclosed in the press release.
Investors will note that the credit outlook upgrade by India Ratings to Positive from Stable signals improved perception of the company's debt-servicing capacity. The company has completed two acquisitions, QliniQ and ABCnow, in Europe, which investors will observe could influence future revenue mix and integration costs in subsequent quarters.
Sector / Market Context
India's pharmaceutical exports have been a consistent contributor to overall merchandise exports, with the sector supplying generics to regulated markets including the US, UK, and Australia. The UK and European generic markets have seen increased demand for affordable formulations, a backdrop relevant to reading Marksans Pharma's 74.7% YoY growth in UK and Europe revenues this quarter.